Q1 Results

[anonymous]

Haven’t seen Augmentin performance being called out on results slides for a long time.

 

[anonymous]

Haven’t seen Augmentin performance being called out on results slides for a long time.

Yup- Augmentin up 38% to 177m.
Inclusion of this demonstrates how weak the gsk story is.
Camlipixant the new chronic cough breakthrough showed comparable efficacy to other medicines in it's class how can this be considered a breakthrough product?
Thank goodness for Shingrix, without it we'd have only a 1/4 leg to stand on.
Oncology contributes little and looking down the road will contribute little.
How can these results and research sway investors and analysts in a positive way?

 

[anonymous]

Yup- Augmentin up 38% to 177m.
Inclusion of this demonstrates how weak the gsk story is.
Camlipixant the new chronic cough breakthrough showed comparable efficacy to other medicines in it's class how can this be considered a breakthrough product?
Thank goodness for Shingrix, without it we'd have only a 1/4 leg to stand on.
Oncology contributes little and looking down the road will contribute little.
How can these results and research sway investors and analysts in a positive way?

We all know our company is in the shitter.